Crinetics Pharmaceuticals (CRNX) Accumulated Expenses (2017 - 2026)

Crinetics Pharmaceuticals' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $25.8 million for Q1 2026.

• In Q1 2026, Accumulated Expenses rose 55.32% year-over-year to $25.8 million; the TTM figure through Mar 2026 stood at $25.8 million (up 55.32% YoY), while the FY2025 annual figure was $35.6 million, up 23.16% from the prior year.
• Accumulated Expenses was $25.8 million for Q1 2026 at Crinetics Pharmaceuticals, down from $35.6 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $35.6 million in Q4 2025 to a low of $4.5 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $17.2 million across 5 years, with a median of $14.8 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses surged 137.03% in 2024, then gained 6.97% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $9.1 million in 2022, then jumped by 59.86% to $14.5 million in 2023, then jumped by 98.99% to $28.9 million in 2024, then rose by 23.16% to $35.6 million in 2025, then decreased by 27.51% to $25.8 million in 2026.
• The last three Accumulated Expenses figures came in at $25.8 million (Q1 2026), $35.6 million (Q4 2025), and $32.4 million (Q3 2025), per Business Quant data.